202114-53-2
202114-53-2
Chemical Structure
Fmoc-leucine-13C
- CAS No.: 202114-53-2
- Formula:C2013CH23NO4
- Molecular Weight:354.40
IUPAC Name: (((9H-fluoren-9-yl)methoxy)carbonyl)-L-leucine-1-13C
InChIKey: CBPJQFCAFFNICX-CHPITSPMSA-N
SMILES: CC(C)C[C@@H]([13C](O)=O)NC(OCC1C2=CC=CC=C2C3=CC=CC=C31)=O
Biological Activity: Fmoc-leucine-13C is a 13C-labeled Boc-GlycineFmoc-leucine (HY-101064).
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fmoc-leucine-13C | 99.90% | Fmoc-leucine-13C is a 13C-labeled Boc-GlycineFmoc-leucine (HY-101064). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine (Standard) | ≥98% | Fmoc-leucine (Standard) is the analytical standard of Fmoc-leucine (HY-101064). This product is intended for research and analytical applications. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-d10 | 99.40% | Fmoc-leucine-d10 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-15N | 98.5% | Fmoc-leucine-15N is a 15N-labeled and 15N-labled Fmoc-leucine (HY-101064). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-13C6,15N | 95.12% | Fmoc-leucine-13C6,15N is a 15N-labeled and 13C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine-d3 | 99.25% | Fmoc-leucine-d3 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fmoc-leucine | 99.9% | Fmoc-Leucine (N-FMOC-leucine) is an anti-inflammatory agent that not only promotes extracellular Ca2+ influx but also facilitates intracellular Ca2+ release. Fmoc-Leucine is a selective ligand for PPARγ (Ki = 15 μM), exhibiting insulin-sensitizing effects but with weak fatogenic activity. Fmoc-Leucine exhibits unique self-assembly properties and can form transient gels, stable gels, or crystals/2D sheets through different pathways. Fmoc-Leucine can be used in the research of diabetes, colitis, and bladder cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
